Adenoviral vectors encoding an antibody fused to a CD4 extracellular domain
AssigneeTransgene S.A.
InventorsPierre Leroy, Majid Mehtali
Life of this patent
Estimating the term…
Abstract
Genetically modified cell implant comprising an exogenous nucleotide sequence coding for all or part of an antibody, method for the preparation of such an implant and its therapeutic use for the treatment or prevention of an acquired disease. The invention also concerns an adenoviral vector for the expression of one or more proteins capable of forming a multimer, viral particles and cells containing the adenoviral vector, a pharmaceutical composition and its therapeutic use.
Claims34
Implant of genetically modified cells comprising an exogenous nucleotide sequence encoding all or part of an antibody, said exogenous nucleotide sequence being placed under the control of the elements necessary for its expression and for the secretion of said antibody.
Recombinant adenoviral vector comprising an exogenous nucleotide sequence encoding all or part of an antibody and placed under the control of the elements necessary for its expression, wherein said antibody is modified by a toxic or immunopotentiating substance.
Recombinant adenoviral vector comprising an exogenous nucleotide sequence encoding all or part of one or more protein(s) of interest capable of forming a multimer, such as a dimer or a tetramer, in a host cell;
- the said exogenous nucleotide sequence being placed under the control of the elements necessary for its expression, said vector being derived from an adenovirus of human, canine, avian, bovine, murine, ovine, porcine or simian origin or a hybrid comprising adenoviral genome fragments of different origins.
Dependencies are inferred from the claim text.